Skip to main content
OTCMKTS:AFFY

Affymax Competitors

$0.08
+0.01 (+14.29 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.07
$0.09
50-Day Range
$0.06
$0.10
52-Week Range
$0.02
$0.26
Volume6,725 shs
Average Volume56,247 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta2.77

Competitors

Affymax (OTCMKTS:AFFY) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying AFFY stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Affymax, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Affymax (OTCMKTS:AFFY) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Affymax and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Amgen29.42%95.55%15.52%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Affymax and Amgen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Amgen291402.48

Amgen has a consensus price target of $255.6190, suggesting a potential upside of 1.91%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Affymax.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. 1.6% of Affymax shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Affymax and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Amgen$23.36 billion6.17$7.84 billion$14.8216.93

Amgen has higher revenue and earnings than Affymax.

Summary

Amgen beats Affymax on 7 of the 9 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 1.6% of Affymax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gilead Sciences and Affymax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences091302.59
Affymax0000N/A

Gilead Sciences currently has a consensus price target of $99.7391, suggesting a potential upside of 47.87%. Given Gilead Sciences' higher possible upside, equities analysts plainly believe Gilead Sciences is more favorable than Affymax.

Volatility & Risk

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
AffymaxN/AN/AN/A

Earnings & Valuation

This table compares Gilead Sciences and Affymax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.77$5.39 billion$6.1410.99
AffymaxN/AN/AN/AN/AN/A

Gilead Sciences has higher revenue and earnings than Affymax.

Summary

Gilead Sciences beats Affymax on 7 of the 9 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Affymax and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings & Valuation

This table compares Affymax and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Vertex Pharmaceuticals$4.16 billion13.23$1.18 billion$4.2949.58

Vertex Pharmaceuticals has higher revenue and earnings than Affymax.

Risk & Volatility

Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 1.6% of Affymax shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Affymax and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Vertex Pharmaceuticals041612.86

Vertex Pharmaceuticals has a consensus target price of $293.4737, suggesting a potential upside of 37.99%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Affymax.

Summary

Vertex Pharmaceuticals beats Affymax on 8 of the 10 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Regeneron Pharmaceuticals and Affymax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Affymax0000N/A

Regeneron Pharmaceuticals presently has a consensus price target of $656.3810, indicating a potential upside of 29.43%. Given Regeneron Pharmaceuticals' higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Affymax.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Affymax's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.91$2.12 billion$21.4723.62
AffymaxN/AN/AN/AN/AN/A

Regeneron Pharmaceuticals has higher revenue and earnings than Affymax.

Profitability

This table compares Regeneron Pharmaceuticals and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
AffymaxN/AN/AN/A

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Affymax on 8 of the 9 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Biogen and Affymax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen4141202.27
Affymax0000N/A

Biogen presently has a consensus price target of $305.5714, indicating a potential upside of 11.51%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Affymax.

Valuation and Earnings

This table compares Biogen and Affymax's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.87$5.89 billion$33.578.16
AffymaxN/AN/AN/AN/AN/A

Biogen has higher revenue and earnings than Affymax.

Profitability

This table compares Biogen and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
AffymaxN/AN/AN/A

Risk and Volatility

Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Summary

Biogen beats Affymax on 7 of the 9 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Affymax and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Alexion Pharmaceuticals015402.21

Alexion Pharmaceuticals has a consensus target price of $159.3158, indicating a potential downside of 7.37%. Given Alexion Pharmaceuticals' higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than Affymax.

Profitability

This table compares Affymax and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Affymax has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Affymax and Alexion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Alexion Pharmaceuticals$4.99 billion7.62$2.40 billion$9.7417.66

Alexion Pharmaceuticals has higher revenue and earnings than Affymax.

Summary

Alexion Pharmaceuticals beats Affymax on 8 of the 9 factors compared between the two stocks.


Affymax Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$250.83+0.6%$144.12 billion$23.36 billion20.23Analyst Report
Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$67.45+0.3%$84.59 billion$22.45 billion69.54
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$212.68+0.2%$55.06 billion$4.16 billion26.85
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$507.14+1.2%$54.33 billion$7.86 billion18.54Earnings Announcement
Insider Selling
Biogen logo
BIIB
Biogen
1.7$274.02+1.6%$41.26 billion$14.38 billion9.07
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$171.99+0.3%$38.01 billion$4.99 billion40.18Analyst Revision
Seagen logo
SGEN
Seagen
1.7$144.77+3.9%$26.27 billion$916.71 million57.00
Incyte logo
INCY
Incyte
1.6$82.37+2.1%$18.12 billion$2.16 billion-52.46Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$96.11+2.0%$16.49 billion$876.29 million-43.49Analyst Report
News Coverage
Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$133.36+0.7%$15.68 billion$219.75 million-17.03
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$75.60+0.1%$13.82 billion$1.70 billion17.30Insider Selling
Novavax logo
NVAX
Novavax
1.8$127.82+8.1%$9.47 billion$18.66 million-24.49Earnings Announcement
Analyst Report
Gap Down
Repligen logo
RGEN
Repligen
1.9$171.60+2.2%$9.42 billion$270.24 million209.27Analyst Report
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.49+0.6%$8.76 billion$1.45 billion18.49Earnings Announcement
Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.15+0.8%$8.71 billion$788.10 million99.09Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$25.16+1.9%$7.88 billion$967.78 million52.42Earnings Announcement
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.48+0.5%$6.09 billion$195.99 million265.50Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.31+1.7%$5.26 billion$1.12 billion77.73Earnings Announcement
Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23+2.4%$3.72 billion$806.43 million-8.67Analyst Revision
Alkermes logo
ALKS
Alkermes
1.2$22.44+0.4%$3.60 billion$1.17 billion-48.78Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60+0.3%$3.14 billion$1.11 billion18.84Analyst Report
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22+4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
OPKO Health logo
OPK
OPKO Health
1.9$3.33+2.7%$2.23 billion$901.90 million-18.50Insider Buying
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$12.49+2.8%$2.22 billion$48.83 million-16.43Earnings Announcement
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$132.71+0.1%$2.20 billionN/A-11.99Earnings Announcement
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.35+4.1%$2.09 billion$120.28 million-126.62Analyst Report
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$25.40+0.0%$1.96 billion$638.60 million-9.77
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16+1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.47+1.7%$1.51 billion$102.43 million-17.45Analyst Report
Analyst Revision
Curis logo
CRIS
Curis
0.9$16.27+39.6%$1.49 billion$10 million-19.84High Trading Volume
Unusual Options Activity
News Coverage
Trading Halted
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.56+4.7%$1.31 billion$82.27 million-16.00Earnings Announcement
Analyst Report
Gap Down
Innoviva logo
INVA
Innoviva
1.1$12.37+1.9%$1.25 billion$261.02 million6.31
Codexis logo
CDXS
Codexis
1.5$17.79+3.1%$1.15 billion$68.46 million-50.83Earnings Announcement
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$25.59+4.6%$1.01 billion$3.57 million-11.48Earnings Announcement
MannKind logo
MNKD
MannKind
1.4$4.02+9.5%$1.00 billion$63.04 million-19.14News Coverage
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$17.80+0.2%$989.04 million$227.19 million49.45Earnings Announcement
Analyst Report
Analyst Revision
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.25+3.7%$830.76 million$35.22 million-5.29Earnings Announcement
Analyst Downgrade
Gap Down
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.05+7.0%$700.99 million$36.13 million-15.00Analyst Report
Insider Buying
High Trading Volume
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$19.19+4.0%$697.13 millionN/A0.00
Agenus logo
AGEN
Agenus
1.6$3.03+2.3%$674.00 million$150.05 million-2.78Earnings Announcement
Analyst Upgrade
Analyst Revision
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.07+1.0%$661.66 million$150,000.00-4.39Earnings Announcement
Analyst Report
Osiris Therapeutics logo
OSIR
Osiris Therapeutics
0.6$18.99+0.0%$655.69 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.38+1.1%$632.42 million$322.07 million-4.17Earnings Announcement
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.69+12.7%$627.91 million$59.29 million-24.60Earnings Announcement
Analyst Upgrade
High Trading Volume
Analyst Revision
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.71+1.8%$597.07 million$143.01 million-1.09Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$17.75+2.5%$588.63 million$252 million-1.81Earnings Announcement
Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.13+0.3%$487.38 million$109.33 million-2.30Upcoming Earnings
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.66+3.0%$485.72 million$22.27 million-4.25Gap Down
Verastem logo
VSTM
Verastem
1.1$2.80+6.4%$480.67 million$17.46 million-1.99Earnings Announcement
News Coverage
Geron logo
GERN
Geron
1.4$1.38+0.7%$439.57 million$460,000.00-3.94Earnings Announcement
News Coverage
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.